This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maffia, P. Articles by Cirino, G. Search for Related Content PubMed PubMed Citation Articles by Maffia, P. Articles by Cirino, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Related Collections Restenosis Animal models of human disease Endothelium/vascular type/nitric oxide

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:263.)
© 2002 American Heart Association, Inc.

Vascular Biology

Beneficial Effects of NO-Releasing Derivative of Flurbiprofen (HCT-1026) in Rat Model of Vascular Injury and Restenosis

Pasquale Maffia; Angela Ianaro; Raffella Sorrentino; Laura Lippolis; Francesco M. Maiello; Piero del Soldato; Armando Ialenti; Giuseppe Cirino

From the Department of Experimental Pharmacology (A. Ianaro, R.S., A. Ialenti, G.C.), University of Naples Federico II, Naples, Italy; ASL 1 "Ospedale dei Pellegrini," Department of Diagnostic Services (F.M.M.), Anatomy and Pathologic Histology Service, Naples, Italy; NicOx SA (P.d.S.), Sophia Antipolis, France; and Department of Pharmaceutical Science (P.M., L.L.), University of Salerno, Italy.

Correspondence to Dr Giuseppe Cirino, Dipartimento di Farmacologia Sperimentale, via Domenico Montesano 49, 80131 Napoli, Italy. E-mail cirino{at}unina.it

One of the major problems related to the percutaneous transluminal coronary angioplasty technique is the renarrowing of the vessel, a phenomenon known as restenosis. NO and nonsteroidal anti-inflammatory drugs have been shown to play a role in this pathology. The main problem with the use of conventional NO donors is that they affect blood pressure and flow, and for these reasons, they cannot be used safely in clinical practice. The aim of this study was to evaluate, with the use of a rat model of balloon angioplasty, whether a structural derivative of flurbiprofen, containing an added NO-releasing moiety (HCT-1026), is able to reduce or prevent neointimal formation. Rats were treated for 14 days with equimolar doses of flurbiprofen (2, 7, and 21 mg/kg) or HCT-1026 (3, 10, and 30 mg/kg). After this 14-day treatment, HCT-1026 but not flurbiprofen significantly modified the neointima/media ratio. The reduction in the neointimal proliferation obtained with HCT-1026 was well correlated with an increase in nitrite/nitrate plasma levels and a reduced cell proliferation. Neither HCT-1026 nor flurbiprofen affected inducible NO synthase induction in injured vessels. In conclusion, HCT-1026 caused a significant reduction in restenosis that appears to be directly related to NO release. HCT-1026 may prove to be beneficial in preventing or delaying restenosis in humans.

Key Words: NSAIDs • HCT-1026 • nitric oxide • restenosis • balloon angioplasty

This article has been cited by other articles:

				P. Maffia, G. Grassia, P. Di Meglio, R. Carnuccio, L. Berrino, P. Garside, A. Ianaro, and A. Ialenti Neutralization of Interleukin-18 Inhibits Neointimal Formation in a Rat Model of Vascular Injury Circulation, August 1, 2006; 114(5): 430 - 437. [Abstract] [Full Text] [PDF]